Adicet Bio Highlights ADI-001 Expansion, Persistence and Pharmacodynamic Profile from Ongoing Phase 1 Study at the 65th American Society of Hematology (ASH) Annual Meeting

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, today announced that an abstract outlining PK and PD profiling data from the Company’s ongoing Phase 1 study of ADI-001 for the potential treatment of relapsed or refractory aggressive B-cell NHL was made available as part of the 65^th ASH Annual Meeting, being held December 9-12, 2023 in San Diego, California. The data will be provided during a poster presentation at the ASH Annual Meeting on Sunday, December 10, 2023.

“We are pleased to share encouraging observations from the pharmacokinetic and pharmacodynamic analyses of ADI-001 at ASH, further characterizing its potential as a best-in-class allogeneic CAR T platform. The data presented today showed dose-dependent expansion and persistence that met or exceeded that in prescribing information of approved autologous CD19 CAR T therapies, supporting ADI-001’s potential as an effective therapeutic option for patients with advanced cancers,” said Francesco Galimi, M.D., Ph.D., Chief Medical Officer. “Historically, expansion and persistence of cell therapy products and release of functional cytokines have correlated with patient outcomes. We remain on track to provide a clinical update from the Phase 1 study in NHL patients in the second half of 2024."

Data highlights included in the ASH presentation were as follows:

• Robust dose-dependent expansion and persistence of ADI-001 were observed using three different methodologies for measuring exposure.
• ADI-001 displayed a strong exposure profile and was positively associated with both PD correlates and clinical response, as supported by the following:
  • At DL3 and DL4, ADI-001 Cmax and Tmax that met or exceeded that in prescribing information of approved autologous CD19 CAR T therapies.
  • Increasing dose levels showed higher Cmax and AUC and were associated with patient clinical responses.
  • ADI-001 stimulation and proliferation were associated with peak levels of CAR+ cells and higher production of polyfunctional cytokines, particularly in patients whose best overall response was complete response or partial response.
  • Elevating levels of endogenous cytokines, comprising stem cell factor and IL-15, may potentially contribute to increased ADI-001 expansion and clinical response.
  • ADI-001 exposure or clinical response showed no correlation with the degree of shared HLA alleles between patient and ADI-001.

Details of the poster presentation are as follows: